Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by Caxton Associates LP

Caxton Associates LP lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 13,000 shares of the company’s stock after purchasing an additional 800 shares during the period. Caxton Associates LP’s holdings in Teva Pharmaceutical Industries Limited were worth $432,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Earnest Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries Limited by 39.5% during the second quarter. Earnest Partners LLC now owns 2,992,743 shares of the company’s stock worth $99,419,000 after purchasing an additional 847,451 shares during the last quarter. Westover Capital Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter worth $942,000. State Street Corp grew its holdings in shares of Teva Pharmaceutical Industries Limited by 5.1% during the second quarter. State Street Corp now owns 4,763,692 shares of the company’s stock worth $158,254,000 after purchasing an additional 232,924 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in shares of Teva Pharmaceutical Industries Limited by 308.1% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 75,900 shares of the company’s stock worth $2,521,000 after purchasing an additional 57,300 shares during the last quarter. Finally, San Francisco Sentry Investment Group CA bought a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter worth $106,000. Institutional investors own 56.75% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/10/13/teva-pharmaceutical-industries-limited-teva-shares-bought-by-caxton-associates-lp.html.

Several brokerages have recently commented on TEVA. Piper Jaffray Companies set a $23.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Friday, October 6th. Wells Fargo & Company set a $20.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Wednesday, October 4th. Morgan Stanley set a $15.00 target price on Teva Pharmaceutical Industries Limited and gave the stock an “underweight” rating in a report on Thursday, October 5th. Cowen and Company restated a “market perform” rating and set a $18.00 target price (down previously from $30.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, October 4th. Finally, Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, October 4th. Five analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and an average target price of $27.63.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 15.06 on Friday. The company’s market capitalization is $15.30 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $15.01 and a 1-year high of $44.49. The firm has a 50-day moving average price of $16.76 and a 200-day moving average price of $26.28.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period last year, the company earned $1.25 earnings per share. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.25 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th were paid a $0.085 dividend. This represents a $0.34 annualized dividend and a dividend yield of 2.24%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -15.36%.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit